Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway.
ADCC
CD4-induced
escape
neutralizing antibody
selection
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
02
10
2019
accepted:
22
11
2019
entrez:
11
1
2020
pubmed:
11
1
2020
medline:
23
10
2020
Statut:
epublish
Résumé
Both neutralization and antibody-dependent cellular cytotoxicity (ADCC) may be required for effective protection against HIV-1 infection. While there is extensive information on the targets of early neutralizing antibody (nAb) responses, much less is known about the targets of ADCC responses, which are more difficult to characterize. In four individuals recruited during acute HIV-infection, ADCC responses were detected 3-7 weeks prior to nAb responses. To determine the relative influence of ADCC and nAb responses on virus evolution, we performed an in-depth investigation of one individual (CAP63) who showed the highest nAb and ADCC responses. Both nAbs and ADCC antibodies targeted the V4 region of the Env, although there were some differences in epitope recognition. We identified accelerated viral evolution in this region concurrent with emergence of nAb activity, but not ADCC activity. Deep sequencing demonstrated that most nAb escape mutations were strongly selected for, however one nAb escape mutation that rendered the virus highly susceptible to autologous ADCC responses, was suppressed despite not affecting viral fitness. This escape mutation also rendered the virus more sensitive to autologous responses, as well as monoclonal antibodies targeting CD4-induced epitopes, compared to the wildtype virus. In conclusion, ADCC responses and nAbs in donor CAP63 recognized overlapping but unique epitopes in the V4 region, and while ADCC activity was present prior to nAbs, it did not drive viral evolution during this time. However, ADCC responses may select against nAb escape pathways that expose other common ADCC epitopes thereby restricting viral replication and expansion.
Identifiants
pubmed: 31921139
doi: 10.3389/fimmu.2019.02875
pmc: PMC6919271
doi:
Substances chimiques
Antibodies, Neutralizing
0
Epitopes, T-Lymphocyte
0
HIV Antibodies
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2875Subventions
Organisme : NIH HHS
ID : K01 OD024877
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI064518
Pays : United States
Informations de copyright
Copyright © 2019 Mielke, Bandawe, Pollara, Abrahams, Nyanhete, Moore, Thebus, Yates, Kappes, Ochsenbauer, Garrett, Abdool Karim, Tomaras, Montefiori, Morris, Ferrari and Williamson.
Références
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E992-9
pubmed: 25681373
EMBO J. 1992 Feb;11(2):585-91
pubmed: 1537337
J Virol. 2008 Dec;82(24):12449-63
pubmed: 18842730
Clin Exp Immunol. 1988 Sep;73(3):343-7
pubmed: 3208446
Nat Commun. 2016 Mar 03;7:10844
pubmed: 26936020
J Virol. 2008 Feb;82(4):1860-9
pubmed: 18057243
Sci Transl Med. 2014 Mar 19;6(228):228ra39
pubmed: 24648342
Curr Opin HIV AIDS. 2009 Sep;4(5):373-9
pubmed: 20048700
J Virol. 2011 Jun;85(11):5465-75
pubmed: 21450829
Nature. 2012 Oct 18;490(7420):417-20
pubmed: 22960785
Mol Biol Evol. 2007 Aug;24(8):1596-9
pubmed: 17488738
J Virol. 2007 Jun;81(12):6187-96
pubmed: 17409164
J Virol. 2012 Mar;86(5):2715-28
pubmed: 22190722
Nature. 2013 Apr 25;496(7446):469-76
pubmed: 23552890
J Virol. 2018 Mar 28;92(8):
pubmed: 29386288
Proc Natl Acad Sci U S A. 2011 May 3;108(18):7505-10
pubmed: 21502492
Nat Med. 2000 Apr;6(4):443-6
pubmed: 10742152
PLoS One. 2014 Feb 04;9(2):e87572
pubmed: 24504509
Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20166-71
pubmed: 22135472
Curr Opin Virol. 2015 Apr;11:137-47
pubmed: 25913818
Curr HIV Res. 2013 Jul;11(5):378-87
pubmed: 24191939
Proc Natl Acad Sci U S A. 2013 May 28;110(22):9019-24
pubmed: 23661056
Nat Rev Immunol. 2008 Jan;8(1):34-47
pubmed: 18064051
Viruses. 2015 Sep 18;7(9):5115-32
pubmed: 26393642
J Virol. 2012 Apr;86(8):4644-57
pubmed: 22345466
J Virol. 2015 Jan;89(1):545-51
pubmed: 25339767
N Engl J Med. 2012 Apr 5;366(14):1275-86
pubmed: 22475592
Cell. 2016 Apr 7;165(2):449-63
pubmed: 26949186
Glycobiology. 2004 Dec;14(12):1229-46
pubmed: 15175256
Cytometry A. 2011 Aug;79(8):603-12
pubmed: 21735545
Adv Virol. 2012;2012:637208
pubmed: 22611395
PLoS One. 2011;6(9):e22594
pubmed: 21949676
PLoS Pathog. 2012;8(6):e1002739
pubmed: 22719248
J Virol. 2015 Oct;89(20):10303-18
pubmed: 26223634
Nature. 2007 Sep 6;449(7158):101-4
pubmed: 17805298
PLoS One. 2008 Apr 16;3(4):e1954
pubmed: 18414658
AIDS. 2011 Nov 13;25(17):2089-97
pubmed: 21832938
PLoS One. 2013 Sep 23;8(9):e74855
pubmed: 24086385
J Virol. 2016 Oct 28;90(22):10220-10235
pubmed: 27581986
J Virol. 2005 Aug;79(16):10108-25
pubmed: 16051804
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7
pubmed: 18490657
J Virol. 2001 Aug;75(15):6953-61
pubmed: 11435575
PLoS One. 2013 Aug 01;8(8):e69789
pubmed: 23936354
Front Immunol. 2019 May 14;10:1062
pubmed: 31139189
J Virol. 2010 Jul;84(14):7161-73
pubmed: 20444898
J Virol. 2009 Apr;83(8):3556-67
pubmed: 19193811
AIDS. 2013 Feb 20;27(4):507-18
pubmed: 23370465
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):E69-78
pubmed: 23237851
J Virol. 1993 Aug;67(8):4557-65
pubmed: 8331723
J Virol. 2009 Jan;83(2):791-801
pubmed: 18971271